
    
      A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the
      Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or
      Ischaemic Stroke in Patients with Type 2 Diabetes
    
  